Speaker Profile
M.D., President and CSO, OncoTracker, Inc
Biography
Dr. James R Berenson, MD is the Founder, President and Chief Scientific Officer of OncoTracker, Inc., an immuno-oncology company focused on both diagnostics and therapeutics for cancer patients with a particular focus on Solubilized (serum) B-Cell Maturation Antigen (sBCMA). Dr. Berenson has his clinical practice in West Hollywood, California, where he specializes in the treatment of patients with multiple myeloma, MGUS, amyloidosis, Waldenstrom’s macroglobulinemia, and metastatic bone disease. Additionally, Dr. Berenson is the founder of the Institute for Myeloma & Bone Cancer Research and has specialized in research related to myeloma and metastatic bone disease both in the basic and clinical areas for more than 20 years. He has been involved in multiple major clinical and scientific breakthroughs that have brought new treatments for patients with these diseases resulting in improved outcomes. He serves as a member of the National Institutes of Health – Center for Scientific Review, Clinical Oncology Study Section. He is a member of the Scientific Boards of the MMRF, IMF, LLS and other groups involved in my multiple myeloma and bone metastases.
Liquid Biopsy Showcase:
OncoTracker, Inc.
Private, revenue-generating, immuno-oncology company focused on both diagnostics and therapeutics for cancer patients.
Novel Biomarker sBCMA Development / Utility In Cancer
Review the discovery, ongoing development and potential utility of the novel biomarker Serum B-cell Maturation Antigen (sBCMA) in multiple myeloma, chronic lymphocytic leukemia and other cancer and conditions.
Session Abstract – PMWC 2020 Silicon Valley
The PMWC 2020 Liquid Biopsy Showcase will provide a 15-minute time slot for selected liquid biopsy companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies that advance the development of screening tests for oncology, immunotherapy, and other areas, based on detection and identification of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating RNA, circulating microRNAs, or extracellular vesicle (exosomes).
